TG 100801

Drug Profile

TG 100801

Alternative Names: TG 100572; TG100801

Latest Information Update: 04 Mar 2011

Price : $50

At a glance

  • Originator TargeGen
  • Class Anti-inflammatories; Benzazepines; Benzoates; Eye disorder therapies; Pyrrolidines; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Eye disorders

Most Recent Events

  • 04 Mar 2011 No development reported - Phase-II for Age-related macular degeneration in USA (Ophthalmic)
  • 04 Mar 2011 No development reported - Preclinical for Diabetic macular oedema in USA (Ophthalmic)
  • 04 Mar 2011 No development reported - Preclinical for Diabetic retinopathy in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top